BJMO - volume 17, issue 1, january 2023
B. Depreitere MD, PhD, S. Schelfaut MD, F. Sinnaeve MD, H. Wafa MD, M. Lambrecht MD, PhD, M. Christiaens MD, PhD, M. Delforge MD, PhD, F.J. Sherida H. Woei-A-Jin MD, PhD, P. Brys MD, M. Renard MD, R. Sciot MD, PhD, J-F. Daisne MD, PhD
Primary bone tumours of the spine are relatively rare when compared to metastatic lesions and haematopoietic neoplasms. This often results in misdiagnosis leading to a high incidence of inadvertent intralesional surgery, which is associated in many cases with worse progression-free survival and overall survival. Based on evidence and consensus, a protocol was designed at the University Hospitals Leuven, intended to guide all possibly involved caregivers in different clinical situations. The protocol raises awareness of potentially suspicious situations and provides expert input to avoid unfortunate decisions, even in situations with alarming neurological deficits.
(BELG J MED ONCOL 2023;17(1):4–10)
Read moreBJMO - volume 12, issue 2, march 2018
W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, J. Mebis MD, M. Renard MD, H. Wildiers MD, PhD
Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.
(BELG J MED ONCOL 2018;12(2):51–60)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.